Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repetitive Acute Intermittent Hypoxia for Spinal Cord Repair
NCT03780829Phase 1Terminated
- Sponsor
- VA Office of Research & Development
- Start
- Feb 2020
- Primary completion
- Feb 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of d-cycloserine in cervical spinal cord injury (4 arms), sponsored by VA Office of Research & Development. Primary endpoints: Change in grip strength at 12 weeks, Change in pinch strength at 12 weeks and 1 more. Started Feb 2020; status: terminated.
02
Drugs
d-cycloserine
03
Conditions
cervical spinal cord injury
Beyond the preview
Go deeper on NCT03780829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780829.